PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 34180140-9 2021 Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment. ricolinostat 110-117 steroid sulfatase Mus musculus 63-66 34958116-3 2022 In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21. ricolinostat 90-98 histone deacetylase 6 Mus musculus 67-88 34958116-3 2022 In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21. ricolinostat 90-98 transformation related protein 53, pseudogene Mus musculus 132-135 34958116-3 2022 In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21. ricolinostat 90-98 transformation related protein 53, pseudogene Mus musculus 172-175 34958116-3 2022 In the present study, it was revealed that a specific inhibitor of histone deacetylase 6, ACY-1215, caused increased acetylation of p53 in breast cancer cells with mutated p53, which was accompanied by increased expression of p21. ricolinostat 90-98 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 226-229 34958116-4 2022 These results suggested that ACY-1215 may lead to enhanced transcriptional activity of p53. ricolinostat 29-37 transformation related protein 53, pseudogene Mus musculus 87-90 34958116-6 2022 Furthermore, ACY-1215 displayed a synergistic effect with specific inhibitors of ATM, an activator of Akt, in inducing cancer cell apoptosis and inhibiting their motility. ricolinostat 13-21 ataxia telangiectasia mutated Mus musculus 81-84 34958116-6 2022 Furthermore, ACY-1215 displayed a synergistic effect with specific inhibitors of ATM, an activator of Akt, in inducing cancer cell apoptosis and inhibiting their motility. ricolinostat 13-21 thymoma viral proto-oncogene 1 Mus musculus 102-105 34958116-7 2022 More importantly, it was observed that combination of ACY-1215 and ATM inhibitors exhibited markedly more potent antitumor activity than the individual compound in xenograft mouse models of breast cancer with mutant p53. ricolinostat 54-62 transformation related protein 53, pseudogene Mus musculus 216-219 34958116-8 2022 Collectively, our results demonstrated that ACY-1215 is a novel chemotherapeutic agent that could restore mutant p53 function in cancer cells with strong antitumor activity, either alone or in combination with inhibitors of the ATM protein kinase. ricolinostat 44-52 transformation related protein 53, pseudogene Mus musculus 113-116 34958116-8 2022 Collectively, our results demonstrated that ACY-1215 is a novel chemotherapeutic agent that could restore mutant p53 function in cancer cells with strong antitumor activity, either alone or in combination with inhibitors of the ATM protein kinase. ricolinostat 44-52 ataxia telangiectasia mutated Mus musculus 228-231 34345305-3 2021 The aim of the present study was to investigate the effect of combination treatment with the proteasome inhibitor bortezomib (BTZ), and ricolinostat (RCS), a specific inhibitor of histone deacetylase 6 (HDAC6), on CAL27 and Detroit562 head and neck cancer cells. ricolinostat 136-148 histone deacetylase 6 Homo sapiens 180-201 34345305-3 2021 The aim of the present study was to investigate the effect of combination treatment with the proteasome inhibitor bortezomib (BTZ), and ricolinostat (RCS), a specific inhibitor of histone deacetylase 6 (HDAC6), on CAL27 and Detroit562 head and neck cancer cells. ricolinostat 136-148 histone deacetylase 6 Homo sapiens 203-208 34180140-0 2021 HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway. ricolinostat 16-23 histone deacetylase 6 Mus musculus 0-5 34180140-0 2021 HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway. ricolinostat 16-23 NLR family, pyrin domain containing 3 Mus musculus 51-56 34180140-0 2021 HDAC6 inhibitor ACY1215 inhibits the activation of NLRP3 inflammasome in acute liver failure by regulating the ATM/F-actin signalling pathway. ricolinostat 16-23 ataxia telangiectasia mutated Mus musculus 111-114 34180140-3 2021 Our findings suggested that ACY1215 treatment ameliorates the pathological hepatic damage of ALF and decreases the serum levels of ALT and AST. ricolinostat 28-35 glutamic pyruvic transaminase, soluble Mus musculus 131-134 34524571-5 2021 Inhibition of HDAC6 via its specific inhibitor ACY1215 restores chemosensitivity of OS-resistant cells. ricolinostat 47-54 histone deacetylase 6 Homo sapiens 14-19 34524571-7 2021 Inhibition of ERRalpha further strengthens ACY1215-increased chemosensitivity of OS-resistant cells. ricolinostat 43-50 estrogen related receptor alpha Homo sapiens 14-22 34329468-4 2021 Screening of 1813 small-molecule compounds resulted in the identification of Ricolinostat (an HDAC6 inhibitor) that can enhance the efficiency of BE3 in human cells (2.45- to 9.21-fold improvement). ricolinostat 77-89 histone deacetylase 6 Homo sapiens 94-99 34329468-7 2021 Meanwhile, combined application of BE3 and Ricolinostat led to >3-fold higher efficiency of correcting a pathogenic mutation in ABCA4 gene related to Stargardt disease in human cells. ricolinostat 43-55 ATP binding cassette subfamily A member 4 Homo sapiens 128-133 34180140-3 2021 Our findings suggested that ACY1215 treatment ameliorates the pathological hepatic damage of ALF and decreases the serum levels of ALT and AST. ricolinostat 28-35 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 139-142 34180140-9 2021 Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment. ricolinostat 110-117 caspase 1 Mus musculus 68-77 34180140-4 2021 Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF. ricolinostat 13-20 ataxia telangiectasia mutated Mus musculus 57-60 34180140-9 2021 Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment. ricolinostat 110-117 interleukin 1 alpha Mus musculus 79-87 34180140-4 2021 Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF. ricolinostat 13-20 H2A.X variant histone Mus musculus 62-72 34180140-9 2021 Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment. ricolinostat 110-117 interleukin 18 Mus musculus 92-97 34180140-4 2021 Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF. ricolinostat 13-20 checkpoint kinase 2 Mus musculus 74-78 34180140-4 2021 Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF. ricolinostat 13-20 transformation related protein 53, pseudogene Mus musculus 80-83 34180140-10 2021 These results indicated that ACY1215 exhibited hepatoprotective properties, which was associated with the inhibition of NLRP3 inflammasome, and this effect of ACY1215 was connected with upregulation of the ATM/F-actin mediated signalling pathways. ricolinostat 29-36 NLR family, pyrin domain containing 3 Mus musculus 120-125 34180140-4 2021 Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF. ricolinostat 13-20 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 85-88 34180140-4 2021 Furthermore, ACY1215 pretreatment increased the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF. ricolinostat 13-20 vinculin Mus musculus 102-110 34180140-5 2021 Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF. ricolinostat 10-17 NLR family, pyrin domain containing 3 Mus musculus 41-46 34180140-5 2021 Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF. ricolinostat 10-17 steroid sulfatase Mus musculus 48-51 34180140-5 2021 Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF. ricolinostat 10-17 caspase 1 Mus musculus 53-62 34180140-5 2021 Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF. ricolinostat 10-17 interleukin 1 alpha Mus musculus 64-72 34180140-10 2021 These results indicated that ACY1215 exhibited hepatoprotective properties, which was associated with the inhibition of NLRP3 inflammasome, and this effect of ACY1215 was connected with upregulation of the ATM/F-actin mediated signalling pathways. ricolinostat 29-36 ataxia telangiectasia mutated Mus musculus 206-209 34180140-10 2021 These results indicated that ACY1215 exhibited hepatoprotective properties, which was associated with the inhibition of NLRP3 inflammasome, and this effect of ACY1215 was connected with upregulation of the ATM/F-actin mediated signalling pathways. ricolinostat 159-166 ataxia telangiectasia mutated Mus musculus 206-209 35167193-6 2022 Next, we demonstrated that inhibition of HDAC6 function, using the HDAC6-specific inhibitor ACY1215 or by transfection with HDAC6 short hairpin RNA (shRNA), can reverse the migratory and invasive phenotype of ARID1A-knockdown cells. ricolinostat 92-99 histone deacetylase 6 Mus musculus 41-46 34180140-5 2021 Moreover, ACY1215 inhibited the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF. ricolinostat 10-17 interleukin 18 Mus musculus 77-82 34180140-6 2021 The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 120-127 ataxia telangiectasia mutated Mus musculus 4-7 34180140-6 2021 The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 120-127 ataxia telangiectasia mutated Mus musculus 54-57 34180140-6 2021 The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 120-127 H2A.X variant histone Mus musculus 59-69 34180140-6 2021 The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 120-127 checkpoint kinase 2 Mus musculus 71-75 34180140-6 2021 The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 120-127 transformation related protein 53, pseudogene Mus musculus 77-80 34180140-6 2021 The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 120-127 cyclin-dependent kinase inhibitor 1A (P21) Mus musculus 82-85 34180140-6 2021 The ATM inhibitor KU55933 could decrease the level of ATM, gamma-H2AX, Chk2, p53, p21, F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 120-127 vinculin Mus musculus 99-107 34180140-7 2021 The F-actin inhibitor cytochalasin B decreased the level of F-actin and vinculin in ALF with ACY1215 pretreatment. ricolinostat 93-100 vinculin Mus musculus 72-80 34180140-9 2021 Cytochalasin B could dramatically increase the level of NLRP3, ASC, caspase-1, IL-1beta and IL-18 in ALF with ACY1215 pretreatment. ricolinostat 110-117 NLR family, pyrin domain containing 3 Mus musculus 56-61 35167193-6 2022 Next, we demonstrated that inhibition of HDAC6 function, using the HDAC6-specific inhibitor ACY1215 or by transfection with HDAC6 short hairpin RNA (shRNA), can reverse the migratory and invasive phenotype of ARID1A-knockdown cells. ricolinostat 92-99 histone deacetylase 6 Mus musculus 67-72 35167193-6 2022 Next, we demonstrated that inhibition of HDAC6 function, using the HDAC6-specific inhibitor ACY1215 or by transfection with HDAC6 short hairpin RNA (shRNA), can reverse the migratory and invasive phenotype of ARID1A-knockdown cells. ricolinostat 92-99 AT rich interactive domain 1A (SWI-like) Mus musculus 209-215 35404520-4 2022 In particular, compound 21, obtained by constantly step-by-step simplification and evolution based on Ricolinostat, a specific HDAC6 inhibitor in Phase II, unexpectedly showed high selectivity (29 fold) and moderate potency (73 nM). ricolinostat 102-114 histone deacetylase 6 Homo sapiens 127-132 35614130-3 2022 Here, through small-molecule screening focusing on epigenetic modifiers during the in vitro Th1 cell differentiation process, we identified that the selective histone deacetylase 6 (HDAC6) inhibitors ricolinostat and nexturastat A (Nex A) promoted Th1 cell differentiation. ricolinostat 200-212 histone deacetylase 6 Mus musculus 182-187 35348191-0 2022 Ricolinostat enhances adavosertib-induced mitotic catastrophe in TP53-mutated head and neck squamous cell carcinoma cells. ricolinostat 0-12 tumor protein p53 Homo sapiens 65-69 35231828-2 2022 In the present study, the effects of ACY-1215, a specific inhibitor of HDAC6, on the acetylation of alpha-tubulin, histone epigenetic modification, spindle formation and embryonic development of early bovine SCNT embryos were studied. ricolinostat 37-45 histone deacetylase 6 Bos taurus 71-76 35159049-7 2022 Additionally, ACY-1215 treatment resulted in a significant reduction in OMM2.5 p-ERK expression levels. ricolinostat 14-22 mitogen-activated protein kinase 1 Homo sapiens 81-84 35123563-5 2022 RESULTS: The small molecule Ricolinostat remarkably promoted the expression of PF4-promoter reporter in the megakaryocytic cell line. ricolinostat 28-40 platelet factor 4 Homo sapiens 79-82 35123563-8 2022 Mechanistically, we found that Ricolinostat enhanced MkP fate mainly by inhibiting the secretion of IL-8 and decreasing the expression of the IL-8 receptor CXCR2. ricolinostat 31-43 C-X-C motif chemokine ligand 8 Homo sapiens 100-104 35123563-9 2022 CONCLUSION: The addition of Ricolinostat to the culture medium promoted MkP differentiation from HSPCs and enhanced the proliferation of MkPs mainly by suppressing the IL-8/CXCR2 pathway. ricolinostat 28-40 C-X-C motif chemokine ligand 8 Homo sapiens 168-172 35123563-9 2022 CONCLUSION: The addition of Ricolinostat to the culture medium promoted MkP differentiation from HSPCs and enhanced the proliferation of MkPs mainly by suppressing the IL-8/CXCR2 pathway. ricolinostat 28-40 C-X-C motif chemokine receptor 2 Homo sapiens 173-178 35159049-8 2022 Through proteome profiling, the attenuation of the microphthalmia-associated transcription factor (MITF) signaling pathway was linked to the observed anti-cancer effects of ACY-1215. ricolinostat 173-181 melanocyte inducing transcription factor Homo sapiens 51-97 35159049-8 2022 Through proteome profiling, the attenuation of the microphthalmia-associated transcription factor (MITF) signaling pathway was linked to the observed anti-cancer effects of ACY-1215. ricolinostat 173-181 melanocyte inducing transcription factor Homo sapiens 99-103 32350373-4 2021 We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies. ricolinostat 84-96 CD38 molecule Homo sapiens 112-116 34998817-0 2022 HDAC6 inhibitor ACY-1215 improves neuropathic pain and its comorbidities in rats of peripheral nerve injury by regulating neuroinflammation. ricolinostat 16-24 histone deacetylase 6 Rattus norvegicus 0-5 34998817-5 2022 The present study was dedicated to exploring the effects of ACY-1215 (a specific HDAC6 inhibitor) on neuroinflammation and behavioral abnormalities associated with NP. ricolinostat 60-68 histone deacetylase 6 Rattus norvegicus 81-86 34998817-8 2022 Moreover, ACY-1215 administration suppressed SNL-induced neuroinflammatory responses (including microgliosis, the elevation of pro-inflammatory factors IL-1beta and TNF-alpha) in ligation of the ipsilateral spinal dorsal horn (iSDH), hippocampus (HPC) and prefrontal cortex (PFC). ricolinostat 10-18 interleukin 1 alpha Rattus norvegicus 152-160 34998817-8 2022 Moreover, ACY-1215 administration suppressed SNL-induced neuroinflammatory responses (including microgliosis, the elevation of pro-inflammatory factors IL-1beta and TNF-alpha) in ligation of the ipsilateral spinal dorsal horn (iSDH), hippocampus (HPC) and prefrontal cortex (PFC). ricolinostat 10-18 tumor necrosis factor Rattus norvegicus 165-174 34998817-9 2022 Mechanistically, MyD88-dependent pro-inflammatory pathways (MyD88/NF-kappaB and MyD88/ERK) were activated in the iSDH following SNL and were inhibited by ACY-1215. ricolinostat 154-162 Eph receptor B1 Rattus norvegicus 86-89 34969757-3 2022 MATERIALS AND METHODS: The anti-tumor effects of ACY-1215, an HDAC6 specific inhibitor, in CCA cell lines were analyzed by cell viability assay, western blotting, flow cytometry, co-immunoprecipitation, and biotinylation assays. ricolinostat 49-57 histone deacetylase 6 Homo sapiens 62-67 34969757-5 2022 RESULTS: ACY-1215 increased the acetyl-form of GRP78 by approximately 50% compared to control, which impaired the translocation of GRP78 to the plasma membrane by 50% through alteration of cellular proliferative signaling via PI3K/AKT. ricolinostat 9-17 heat shock protein family A (Hsp70) member 5 Homo sapiens 47-52 34969757-5 2022 RESULTS: ACY-1215 increased the acetyl-form of GRP78 by approximately 50% compared to control, which impaired the translocation of GRP78 to the plasma membrane by 50% through alteration of cellular proliferative signaling via PI3K/AKT. ricolinostat 9-17 heat shock protein family A (Hsp70) member 5 Homo sapiens 131-136 34969757-5 2022 RESULTS: ACY-1215 increased the acetyl-form of GRP78 by approximately 50% compared to control, which impaired the translocation of GRP78 to the plasma membrane by 50% through alteration of cellular proliferative signaling via PI3K/AKT. ricolinostat 9-17 AKT serine/threonine kinase 1 Homo sapiens 231-234 33915983-4 2021 We found that HDAC6 inhibitors ACY-1215 (1215) and ACY-738 (738) inhibited the proliferation of multiple patient-derived and mouse glioma cells. ricolinostat 31-39 histone deacetylase 6 Homo sapiens 14-19 33458921-0 2021 First-in-Class Selective HDAC6 Inhibitor (ACY-1215) Has a Highly Favorable Safety Profile in Patients with Relapsed and Refractory Lymphoma. ricolinostat 42-50 histone deacetylase 6 Homo sapiens 25-30 33458921-5 2021 BACKGROUND: ACY-1215, ricolinostat, is an oral, first-in-class isoform-selective HDAC6 inhibitor. ricolinostat 12-20 histone deacetylase 6 Homo sapiens 81-86 33458921-5 2021 BACKGROUND: ACY-1215, ricolinostat, is an oral, first-in-class isoform-selective HDAC6 inhibitor. ricolinostat 22-34 histone deacetylase 6 Homo sapiens 81-86 33428788-0 2021 HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin. ricolinostat 17-24 histone deacetylase 6 Homo sapiens 0-5 33428788-2 2021 ACY1215 is a highly effective selective inhibitor of HDAC6, which can inhibit many kinds of tumors. ricolinostat 0-7 histone deacetylase 6 Homo sapiens 53-58 33428788-8 2021 The HDAC6 inhibitor ACY1215 suppressed the proliferation of GBC-SD and SDC-996 cells and promoted the apoptosis of gallbladder cancer cells. ricolinostat 20-27 histone deacetylase 6 Homo sapiens 4-9 33428788-9 2021 The HDAC6 inhibitor ACY1215 increases the chemotherapy effect of gemcitabine and oxaliplatin. ricolinostat 20-27 histone deacetylase 6 Homo sapiens 4-9 33428788-10 2021 ACY1215 could suppress cell proliferation and induce apoptosis of GBC-SD and SGC-996, and increased the chemotherapy effect of gemcitabine and oxaliplatin, which provides a rationale for the combination of HDAC6 selective inhibitors with other anticancer agents in treating gallbladder cancer. ricolinostat 0-7 histone deacetylase 6 Homo sapiens 206-211 33883923-4 2021 The ALF mice model was intervened with HDAC6 inhibitor ACY-1215. ricolinostat 55-63 histone deacetylase 6 Mus musculus 39-44 33883923-14 2021 Conclusion: ACY-1215 could inhibit the activation of M1 macrophages by improving the glycolytic pathway through regulating DNMT1 and DDX3X/NLRP3 signals to alleviate ALF. ricolinostat 12-20 DNA methyltransferase (cytosine-5) 1 Mus musculus 123-128 33883923-14 2021 Conclusion: ACY-1215 could inhibit the activation of M1 macrophages by improving the glycolytic pathway through regulating DNMT1 and DDX3X/NLRP3 signals to alleviate ALF. ricolinostat 12-20 DEAD box helicase 3, X-linked Mus musculus 133-138 33883923-14 2021 Conclusion: ACY-1215 could inhibit the activation of M1 macrophages by improving the glycolytic pathway through regulating DNMT1 and DDX3X/NLRP3 signals to alleviate ALF. ricolinostat 12-20 NLR family, pyrin domain containing 3 Mus musculus 139-144 33835029-5 2021 High-throughput compound screening with this model identified ACY-1215 as a potent latency reversing agent, which could be verified in other cell models and in primary CD4+ T cells from ART-suppressed individuals ex vivo. ricolinostat 62-70 CD4 molecule Homo sapiens 168-171 33654196-7 2021 Significantly, we found that tektin4 loss sensitized TNBC cells, xenograft models, and patient-derived organoid models to the HDAC6-selective inhibitor ACY1215. ricolinostat 152-159 tektin 4 Homo sapiens 29-36 33654196-7 2021 Significantly, we found that tektin4 loss sensitized TNBC cells, xenograft models, and patient-derived organoid models to the HDAC6-selective inhibitor ACY1215. ricolinostat 152-159 histone deacetylase 6 Homo sapiens 126-131 32350373-4 2021 We therefore investigated the potential of the histone deacetylase (HDAC) inhibitor ricolinostat to up-regulate CD38 on MM cells, thereby enhancing the performance of CD38-specific therapies. ricolinostat 84-96 CD38 molecule Homo sapiens 167-171 32350373-5 2021 Using quantitative reverse transcription polymerase chain reaction and flow cytometry, we observed that ricolinostat significantly increases CD38 RNA levels and CD38 surface expression on MM cells. ricolinostat 104-116 CD38 molecule Homo sapiens 141-145 32350373-5 2021 Using quantitative reverse transcription polymerase chain reaction and flow cytometry, we observed that ricolinostat significantly increases CD38 RNA levels and CD38 surface expression on MM cells. ricolinostat 104-116 CD38 molecule Homo sapiens 161-165 32705192-0 2020 ACY-1215, a HDAC6 inhibitor, decreases the dexamethasone-induced suppression of osteogenesis in MC3T3-E1 cells. ricolinostat 0-8 histone deacetylase 6 Mus musculus 12-17 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 83-95 histone deacetylase 6 Homo sapiens 40-45 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 83-95 histone deacetylase 6 Homo sapiens 118-123 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 83-95 tubulin alpha 1b Homo sapiens 141-154 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 83-95 tubulin alpha 1b Homo sapiens 208-221 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 83-95 histone deacetylase 6 Homo sapiens 118-123 33103445-3 2020 In this study, we examined the effect of ricolinostat (ACY-1215), a selective inhibitor of HDAC6, on the development of renal fibrosis in a murine model induced by unilateral ureteral obstruction (UUO). ricolinostat 41-53 histone deacetylase 6 Mus musculus 91-96 33103445-5 2020 Administration of ACY-1215 reduced these fibrotic changes and inhibited UUO-induced expression of transforming growth factor ss1 (TGFss1) and phosphorylation of Smad3, while increasing expression of Smad7. ricolinostat 18-26 SMAD family member 3 Mus musculus 161-166 33103445-5 2020 Administration of ACY-1215 reduced these fibrotic changes and inhibited UUO-induced expression of transforming growth factor ss1 (TGFss1) and phosphorylation of Smad3, while increasing expression of Smad7. ricolinostat 18-26 SMAD family member 7 Mus musculus 199-204 33103445-6 2020 ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney. ricolinostat 0-8 epidermal growth factor receptor Mus musculus 54-86 33103445-6 2020 ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney. ricolinostat 0-8 epidermal growth factor receptor Mus musculus 88-92 33103445-6 2020 ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney. ricolinostat 0-8 thymoma viral proto-oncogene 1 Mus musculus 172-175 33103445-6 2020 ACY-1215 treatment also suppressed phosphorylation of epidermal growth factor receptor (EGFR) and several signaling molecules associated with renal fibrogenesis, including AKT, signal transducer and activator of transcription 3 and nuclear factor kappa light chain enhancer of activated B cells in the injured kidney. ricolinostat 0-8 signal transducer and activator of transcription 3 Mus musculus 177-227 32435850-6 2020 Inhibition of HDAC6 with ricolinostat reduced suppressive activity of M-MDSC, but did not affect PMN-MDSC or delayed tumor growth. ricolinostat 25-37 histone deacetylase 6 Mus musculus 14-19 32615502-10 2020 Altogether, in this study we identified a novel and potent HDAC6-selective inhibitor (~4x more selective than current clinical standards - citarinostat, ricolinostat), which achieves cellular target engagement, efficacy in hematological cancer cells with a promising safety profile and in vitro PK. ricolinostat 153-165 histone deacetylase 6 Homo sapiens 59-64 32572875-0 2020 Histone deacetylase 6 inhibitor ACY1215 ameliorates mitochondrial dynamic and function injury in hepatocytes by activating AMPK signaling pathway in acute liver failure mice. ricolinostat 32-39 histone deacetylase 6 Mus musculus 0-21 32572875-2 2020 The histone deacetylase 6 inhibitor Rocilinostat (ACY1215) has a hepatoprotective effect. ricolinostat 36-48 histone deacetylase 6 Mus musculus 4-25 32572875-2 2020 The histone deacetylase 6 inhibitor Rocilinostat (ACY1215) has a hepatoprotective effect. ricolinostat 50-57 histone deacetylase 6 Mus musculus 4-25 32572875-12 2020 ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models. ricolinostat 0-7 collapsin response mediator protein 1 Mus musculus 69-73 32572875-12 2020 ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models. ricolinostat 0-7 fission, mitochondrial 1 Mus musculus 78-82 32572875-12 2020 ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models. ricolinostat 0-7 mitofusin 1 Mus musculus 137-141 32572875-12 2020 ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models. ricolinostat 0-7 mitofusin 2 Mus musculus 143-147 32572875-12 2020 ACY1215 treatment decreased levels of mitochondrial fission proteins DRP1 and FIS1, and enhanced levels of mitochondrial fusion proteins MFN1, MFN2 and OPA1 in models. ricolinostat 0-7 OPA1, mitochondrial dynamin like GTPase Mus musculus 152-156 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 97-105 histone deacetylase 6 Homo sapiens 40-45 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 97-105 histone deacetylase 6 Homo sapiens 118-123 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 97-105 tubulin alpha 1b Homo sapiens 141-154 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 97-105 tubulin alpha 1b Homo sapiens 208-221 33322608-8 2020 Conversely, the selective inhibition of HDAC6 with the catalytic domain inhibitor, Ricolinostat (ACY-1215), inhibited HDAC6 deacetylation of alpha-tubulin, resulting in a sustained accumulation of acetylated alpha-tubulin up to 24 h in HGSOC cells, did not produce a robust inhibition of HDAC6 protein function. ricolinostat 97-105 histone deacetylase 6 Homo sapiens 118-123 32705192-12 2020 ACY-1215 promoted the GR expression in MC3T3-E1 cells from 1-5 mM while GR receptor expression was increased with 10 mM ACY-1215 treatment. ricolinostat 0-8 nuclear receptor subfamily 3, group C, member 1 Mus musculus 22-24 32178737-10 2020 ACY-1215- and MPT0E028-treated rats had a trend in decreased serum TGF-beta levels, but not statistically significant. ricolinostat 0-8 transforming growth factor alpha Rattus norvegicus 67-75 32754596-3 2020 Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models. ricolinostat 207-219 histone deacetylase 6 Homo sapiens 182-187 32754596-3 2020 Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models. ricolinostat 207-219 mitogen-activated protein kinase kinase 7 Homo sapiens 238-241 32754596-3 2020 Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models. ricolinostat 221-228 histone deacetylase 6 Homo sapiens 182-187 32754596-3 2020 Based on the notion that HDAC inhibitors may reactivate the expression of genes favoring cell response to drugs, the aim of this study was to investigate the interaction between the HDAC6-specific inhibitor ricolinostat (ACY1215) and the MEK-inhibitor selumetinib (AZD6244) to identify effective combinations in prostate cancer models. ricolinostat 221-228 mitogen-activated protein kinase kinase 7 Homo sapiens 238-241 32178737-13 2020 TGF-beta and CRP should be useful biomarkers to monitor the use of ACY1215 in cardiac IR injury. ricolinostat 67-74 C-reactive protein Rattus norvegicus 13-16 32178737-11 2020 ACY1215-treated rats also had higher serum CRP levels compared to control rats (641.6 mug/mL vs. 961.37 +- 64.94 mug/mL, p < 0.05). ricolinostat 0-7 C-reactive protein Rattus norvegicus 43-46 32178737-12 2020 CONCLUSIONS: Our research indicated that HDAC6 inhibition by ACY1215 might reduce infarct size in rats with cardiac IR injury possibly through modulating HIF-1alpha expression. ricolinostat 61-68 histone deacetylase 6 Rattus norvegicus 41-46 32178737-12 2020 CONCLUSIONS: Our research indicated that HDAC6 inhibition by ACY1215 might reduce infarct size in rats with cardiac IR injury possibly through modulating HIF-1alpha expression. ricolinostat 61-68 hypoxia inducible factor 1 subunit alpha Rattus norvegicus 154-164 32178737-13 2020 TGF-beta and CRP should be useful biomarkers to monitor the use of ACY1215 in cardiac IR injury. ricolinostat 67-74 transforming growth factor alpha Rattus norvegicus 0-8 31160511-0 2019 Retraction: In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells. ricolinostat 88-95 histone deacetylase 6 Homo sapiens 58-63 31634464-0 2019 Histone deacetylase 6 inhibitor ACY1215 offers a protective effect through the autophagy pathway in acute liver failure. ricolinostat 32-39 histone deacetylase 6 Mus musculus 0-21 31634464-1 2019 AIM: The purpose of the present study was to elucidate the protective effect of histone deacetylase 6 inhibitor ACY1215 on autophagy pathway in acute liver failure (ALF). ricolinostat 112-119 histone deacetylase 6 Mus musculus 80-101 31634464-11 2019 ACY1215 could induce autophagy in ALF mice and cell model group accompanied with an increase in expression of LC3-II and beclin-1 proteins and down-regulation of p62 protein. ricolinostat 0-7 beclin 1, autophagy related Mus musculus 121-129 31634464-11 2019 ACY1215 could induce autophagy in ALF mice and cell model group accompanied with an increase in expression of LC3-II and beclin-1 proteins and down-regulation of p62 protein. ricolinostat 0-7 nucleoporin 62 Mus musculus 162-165 31356453-3 2019 We show that pharmacological inhibition of HDAC6 using ACY-1215 or global deletion of HDAC6 is sufficient to prevent cisplatin-induced mechanical allodynia, loss of intraepidermal nerve fibers (IENFs), and mitochondrial bioenergetic deficits in DRG neurons and peripheral nerves in male and female mice. ricolinostat 55-63 histone deacetylase 6 Mus musculus 43-48 31500290-8 2019 Pharmacological inhibition of HDACs 1 and 2 with Romidepsin and HDAC6 with ACY-1215 also potently synergized with gemcitabine in a panel of PDAC cell lines, and this drug combination potentiated the antitumor effects of gemcitabine against PDAC xenografts in vivo. ricolinostat 75-83 histone deacetylase 1 Homo sapiens 30-43 31500290-8 2019 Pharmacological inhibition of HDACs 1 and 2 with Romidepsin and HDAC6 with ACY-1215 also potently synergized with gemcitabine in a panel of PDAC cell lines, and this drug combination potentiated the antitumor effects of gemcitabine against PDAC xenografts in vivo. ricolinostat 75-83 histone deacetylase 6 Homo sapiens 64-69 31467965-0 2019 Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. ricolinostat 64-76 histone deacetylase 6 Homo sapiens 48-53 30664664-6 2019 Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux. ricolinostat 50-58 histone deacetylase 6 Mus musculus 34-39 30664664-6 2019 Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux. ricolinostat 50-58 cyclin-dependent kinase 4 Mus musculus 94-98 30664664-6 2019 Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux. ricolinostat 50-58 cyclin D1 Mus musculus 100-109 30664664-6 2019 Co-treatment with CB-5083 and the HDAC6 inhibitor ACY-1215 result in marked downregulation of CDK4, Cyclin D1, and BRCA1 levels without inhibiting autophagic flux. ricolinostat 50-58 breast cancer 1, early onset Mus musculus 115-120 30664664-8 2019 Furthermore, ATM loss severely impairs phosphorylation of 53BP1 following co-treatment with CB-5083 and ACY-1215 in response to gamma irradiation. ricolinostat 104-112 ataxia telangiectasia mutated Mus musculus 13-16 30664664-8 2019 Furthermore, ATM loss severely impairs phosphorylation of 53BP1 following co-treatment with CB-5083 and ACY-1215 in response to gamma irradiation. ricolinostat 104-112 transformation related protein 53 binding protein 1 Mus musculus 58-63 31244662-1 2019 Background: ACY-1215 is a well-known selective histone deacetylase 6 (HDAC6) inhibitor, and it has been considered as a potential therapeutic drug in inflammatory diseases, including acute liver failure (ALF). ricolinostat 12-20 histone deacetylase 6 Mus musculus 47-68 31244662-1 2019 Background: ACY-1215 is a well-known selective histone deacetylase 6 (HDAC6) inhibitor, and it has been considered as a potential therapeutic drug in inflammatory diseases, including acute liver failure (ALF). ricolinostat 12-20 histone deacetylase 6 Mus musculus 70-75 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 43-55 histone deacetylase 6 Mus musculus 23-28 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 43-55 mitogen-activated protein kinase 8 Mus musculus 134-157 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 43-55 mitogen-activated protein kinase 8 Mus musculus 159-162 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 43-55 jun proto-oncogene Mus musculus 134-139 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 57-65 histone deacetylase 6 Mus musculus 23-28 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 57-65 mitogen-activated protein kinase 8 Mus musculus 134-157 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 57-65 mitogen-activated protein kinase 8 Mus musculus 159-162 31390677-2 2020 Here, we reported that HDAC6 inhibition by Ricolinostat (ACY-1215) or CAY10603 led to a remarkable decrease in the phosphorylation of c-Jun N-terminal kinase (JNK) and c-Jun, which preceded its suppressive effects on glioma cell growth. ricolinostat 57-65 jun proto-oncogene Mus musculus 134-139 31634464-12 2019 Moreover, the expression of LC3-II and beclin1 proteins were greatly reduced and the expression of p62 protein was ascended after intervention with 3-MA in ACY1215 group. ricolinostat 156-163 beclin 1, autophagy related Mus musculus 39-46 31634464-12 2019 Moreover, the expression of LC3-II and beclin1 proteins were greatly reduced and the expression of p62 protein was ascended after intervention with 3-MA in ACY1215 group. ricolinostat 156-163 nucleoporin 62 Mus musculus 99-102 31634464-13 2019 SIGNIFICANCE: Histone deacetylase 6 inhibitor ACY1215 could protect acute liver failure mice and L02 cell by inhibiting apoptosis pathway through enhancing autophagy way. ricolinostat 46-53 histone deacetylase 6 Mus musculus 14-35 31311810-5 2019 Reduced tumor burden and improved survival was observed in ARID1Aflox/flox/PIK3CAH1047R OCCC mouse treated with the HDAC6 inhibitor ACY1215 and anti-PD-L1 immune-checkpoint blockade as a result of activation and increased presence of interferon-gamma positive CD8 T cells. ricolinostat 132-139 histone deacetylase 6 Mus musculus 116-121 31311810-5 2019 Reduced tumor burden and improved survival was observed in ARID1Aflox/flox/PIK3CAH1047R OCCC mouse treated with the HDAC6 inhibitor ACY1215 and anti-PD-L1 immune-checkpoint blockade as a result of activation and increased presence of interferon-gamma positive CD8 T cells. ricolinostat 132-139 interferon gamma Mus musculus 234-250 30558483-5 2019 In addition, its structural and energetic behavior was explored with each one of the catalytic domains in the molecular recognition of six selective HDAC6 inhibitors, HPOB, CAY10603, Nexturastat, Rocilinostat, Tubacin and Tubastatin A for DD2, and with the so-called 9-peptide which is DD1-HDAC6 selective substrate. ricolinostat 196-208 histone deacetylase 6 Homo sapiens 149-154 30558483-6 2019 The use of the whole system (DD1-DMB-DD2) showed a tendency toward the ligand affinity of DD2, CAY10603> Tubacin > Rocilinostat > Nexturastat > HPOB > Tubastatin > 9-peptide, which is in line with experimental reports. ricolinostat 115-127 aldo-keto reductase family 1 member C1 Homo sapiens 29-32 30558483-6 2019 The use of the whole system (DD1-DMB-DD2) showed a tendency toward the ligand affinity of DD2, CAY10603> Tubacin > Rocilinostat > Nexturastat > HPOB > Tubastatin > 9-peptide, which is in line with experimental reports. ricolinostat 115-127 aldo-keto reductase family 1 member C2 Homo sapiens 37-40 31571096-5 2019 In the present study, we examined the effect of HDAC6 inhibitor ACY-1215 (Ricolinostat) on cisplatin-induced brain damage and cognitive deficits in mice. ricolinostat 64-72 histone deacetylase 6 Mus musculus 48-53 31571096-5 2019 In the present study, we examined the effect of HDAC6 inhibitor ACY-1215 (Ricolinostat) on cisplatin-induced brain damage and cognitive deficits in mice. ricolinostat 74-86 histone deacetylase 6 Mus musculus 48-53 31571096-7 2019 Mechanistically, HDAC6 inhibitor ACY-1215 enhanced alpha-tubulin acetylation in the hippocampus of cisplatin-treated mice. ricolinostat 33-41 histone deacetylase 6 Mus musculus 17-22 31548177-0 2019 Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. ricolinostat 0-12 vascular endothelial growth factor A Homo sapiens 33-37 31548177-0 2019 Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. ricolinostat 0-12 AKT serine/threonine kinase 1 Homo sapiens 58-61 31548177-0 2019 Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. ricolinostat 14-22 vascular endothelial growth factor A Homo sapiens 33-37 31548177-0 2019 Ricolinostat (ACY-1215) inhibits VEGF expression via PI3K/AKT pathway and promotes apoptosis in osteoarthritic osteoblasts. ricolinostat 14-22 AKT serine/threonine kinase 1 Homo sapiens 58-61 31548177-2 2019 As a selective HDAC6 inhibitor, Ricolinostat (ACY-1215) has demonstrated chondroprotective effects in OA. ricolinostat 32-44 histone deacetylase 6 Homo sapiens 15-20 31548177-2 2019 As a selective HDAC6 inhibitor, Ricolinostat (ACY-1215) has demonstrated chondroprotective effects in OA. ricolinostat 46-54 histone deacetylase 6 Homo sapiens 15-20 31548177-5 2019 PI3K/AKT signaling pathway was suppressed with downregulation of VEGF expression in osteoblasts after ACY-1215 treatment. ricolinostat 102-110 AKT serine/threonine kinase 1 Homo sapiens 5-8 31548177-5 2019 PI3K/AKT signaling pathway was suppressed with downregulation of VEGF expression in osteoblasts after ACY-1215 treatment. ricolinostat 102-110 vascular endothelial growth factor A Homo sapiens 65-69 31548177-7 2019 Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1beta-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts. ricolinostat 128-136 matrix metallopeptidase 9 Homo sapiens 58-62 31548177-7 2019 Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1beta-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts. ricolinostat 128-136 matrix metallopeptidase 13 Homo sapiens 67-72 31548177-7 2019 Moreover, western blotting showed decreased expression of MMP9 and MMP13 in IL-1beta-induced chondrocytes after co-culture with ACY-1215-stimulated osteoblasts. ricolinostat 128-136 interleukin 1 beta Homo sapiens 76-84 31548177-8 2019 These data of immunohistochemistry and micro-CT from OA model mice also demonstrated the weak staining of MMPs in cartilage and prevention of aberrant subchondral bone formation after ACY-1215 injection. ricolinostat 184-192 matrix metallopeptidase 9 Homo sapiens 106-110 31515470-7 2019 We also demonstrate that the selective HDAC6 inhibitors tubacin and ACY-1215, which prevented gp120-mediated deacetylation of tubulin, inhibited the ability of gp120 to promote neurite shortening and cell death. ricolinostat 68-76 histone deacetylase 6 Homo sapiens 39-44 31515470-7 2019 We also demonstrate that the selective HDAC6 inhibitors tubacin and ACY-1215, which prevented gp120-mediated deacetylation of tubulin, inhibited the ability of gp120 to promote neurite shortening and cell death. ricolinostat 68-76 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 94-99 31515470-7 2019 We also demonstrate that the selective HDAC6 inhibitors tubacin and ACY-1215, which prevented gp120-mediated deacetylation of tubulin, inhibited the ability of gp120 to promote neurite shortening and cell death. ricolinostat 68-76 inter-alpha-trypsin inhibitor heavy chain 4 Homo sapiens 160-165 30043566-0 2018 ACY 1215, a histone deacetylase 6 inhibitor, inhibits cancer cell growth in melanoma. ricolinostat 0-8 histone deacetylase 6 Mus musculus 12-33 30728070-11 2019 The frequency, FOXP3 expression, and suppressive function of T regulatory cells (Tregs) were decreased after exposure to ACY-1215 or ACY-241. ricolinostat 121-129 forkhead box P3 Homo sapiens 15-20 30728070-13 2019 After ACY-1215 treatment, increased chromatin accessibility was observed in regions associated with T-cell effector function and memory phenotypes, while condensed chromatin was found in regions encoding the mTOR downstream molecules AKT, SGK1 and S6K. ricolinostat 6-14 serum/glucocorticoid regulated kinase 1 Homo sapiens 239-243 30728070-13 2019 After ACY-1215 treatment, increased chromatin accessibility was observed in regions associated with T-cell effector function and memory phenotypes, while condensed chromatin was found in regions encoding the mTOR downstream molecules AKT, SGK1 and S6K. ricolinostat 6-14 ribosomal protein S6 kinase B1 Homo sapiens 248-251 30551507-0 2019 ACY-1215 exhibits anti-inflammatory and chondroprotective effects in human osteoarthritis chondrocytes via inhibition of STAT3 and NF-kappaB signaling pathways. ricolinostat 0-8 signal transducer and activator of transcription 3 Homo sapiens 121-126 30551507-2 2019 ACY-1215, a selective HDAC6 inhibitor, has been reported to have anti-inflammatory effects. ricolinostat 0-8 histone deacetylase 6 Homo sapiens 22-27 30551507-3 2019 Here, we investigated the anti-inflammatory and chondroprotective effects of ACY-1215 in IL-1beta-stimulated human primary chondrocytes and C28/I2 cells. ricolinostat 77-85 interleukin 1 beta Homo sapiens 89-97 30551507-4 2019 The results suggested that ACY-1215 can markedly suppress the expression of inflammatory factors, including IL-1beta and IL-6 in human primary chondrocytes and C28/I2 cells. ricolinostat 27-35 interleukin 1 beta Homo sapiens 108-116 30551507-4 2019 The results suggested that ACY-1215 can markedly suppress the expression of inflammatory factors, including IL-1beta and IL-6 in human primary chondrocytes and C28/I2 cells. ricolinostat 27-35 interleukin 6 Homo sapiens 121-125 30028995-0 2018 Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. ricolinostat 109-121 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 30028995-0 2018 Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. ricolinostat 109-121 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-55 30028995-0 2018 Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. ricolinostat 109-121 histone deacetylase 6 Homo sapiens 77-98 30028995-0 2018 Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. ricolinostat 123-131 ATP binding cassette subfamily B member 1 Homo sapiens 40-45 30028995-0 2018 Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. ricolinostat 123-131 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 50-55 30028995-0 2018 Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. ricolinostat 123-131 histone deacetylase 6 Homo sapiens 77-98 30028995-3 2018 In this study, we investigated the potential impact of multidrug resistance-linked ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 on the efficacy of ricolinostat, which may present a major hurdle to its development as an anticancer drug in the future. ricolinostat 158-170 ATP binding cassette subfamily B member 1 Homo sapiens 123-128 30028995-3 2018 In this study, we investigated the potential impact of multidrug resistance-linked ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 on the efficacy of ricolinostat, which may present a major hurdle to its development as an anticancer drug in the future. ricolinostat 158-170 ATP binding cassette subfamily G member 2 (Junior blood group) Homo sapiens 133-138 29760044-5 2018 Combined treatment of human and mouse SCLC cell line-derived xenograft tumors with the HDAC6 inhibitor ricolinostat (ACY-1215) and JQ1 demonstrated significant inhibition of tumor growth; this effect was abolished upon depletion of NK cells, suggesting that these innate immune lymphoid cells play a role in SCLC tumor treatment response. ricolinostat 117-125 histone deacetylase 6 Mus musculus 87-92 30728070-9 2019 The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13). ricolinostat 31-39 histone deacetylase 6 Homo sapiens 4-9 30728070-9 2019 The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13). ricolinostat 31-39 interleukin 4 Homo sapiens 122-126 30728070-9 2019 The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13). ricolinostat 31-39 interleukin 5 Homo sapiens 128-132 30728070-9 2019 The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13). ricolinostat 31-39 interleukin 6 Homo sapiens 134-138 30728070-9 2019 The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13). ricolinostat 31-39 interleukin 10 Homo sapiens 140-145 30728070-9 2019 The HDAC6-selective inhibitors ACY-1215 (ricolinostat) and ACY-241 (citarinostat) decreased Th2 cytokine production (i.e. IL-4, IL-5, IL-6, IL-10 and IL-13). ricolinostat 31-39 interleukin 13 Homo sapiens 150-155 30788349-0 2019 Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells. ricolinostat 42-49 histone deacetylase 6 Homo sapiens 0-21 30788349-1 2019 Background: ACY1215 is a selective histone deacetylase 6 (HDAC6) inhibitor, and can suppress tumor growth for many human cancers. ricolinostat 12-19 histone deacetylase 6 Homo sapiens 35-56 30788349-1 2019 Background: ACY1215 is a selective histone deacetylase 6 (HDAC6) inhibitor, and can suppress tumor growth for many human cancers. ricolinostat 12-19 histone deacetylase 6 Homo sapiens 58-63 30788349-8 2019 Conclusions: Selective HDAC6 inhibitor, ACY1215, could inhibit the cell proliferation, migration and invasion, and induce apoptosis of HCT116 colon cancer cells. ricolinostat 40-47 histone deacetylase 6 Homo sapiens 23-28 30551507-5 2019 Furthermore, ACY-1215 exerts potent chondroprotection through the amelioration of cartilage degradation by inhibiting the expression of matrix-degrading proteases, including MMP-1 and MMP-13 in chondrocytes. ricolinostat 13-21 matrix metallopeptidase 1 Homo sapiens 174-179 30551507-5 2019 Furthermore, ACY-1215 exerts potent chondroprotection through the amelioration of cartilage degradation by inhibiting the expression of matrix-degrading proteases, including MMP-1 and MMP-13 in chondrocytes. ricolinostat 13-21 matrix metallopeptidase 13 Homo sapiens 184-190 30551507-6 2019 These effects may be related to ACY-1215 induced down-regulation of NF-kappaB and STAT3 pathways in OA chondrocytes. ricolinostat 32-40 signal transducer and activator of transcription 3 Homo sapiens 82-87 29749542-0 2018 The HDAC6 inhibitor ACY-1215 enhances the anticancer activity of oxaliplatin in colorectal cancer cells. ricolinostat 20-28 histone deacetylase 6 Homo sapiens 4-9 29749542-1 2018 ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. ricolinostat 0-8 histone deacetylase 6 Homo sapiens 51-72 29749542-1 2018 ACY-1215, also known as ricolinostat, is a leading histone deacetylase 6 inhibitor, which is currently being tested in clinical trials for hematological malignancies. ricolinostat 24-36 histone deacetylase 6 Homo sapiens 51-72 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 0-12 microRNA 30d Mus musculus 114-121 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 0-12 thymoma viral proto-oncogene 1 Mus musculus 127-130 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 0-12 mechanistic target of rapamycin kinase Mus musculus 131-135 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 0-12 mitogen-activated protein kinase 1 Mus musculus 140-143 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 14-22 microRNA 30d Mus musculus 114-121 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 14-22 thymoma viral proto-oncogene 1 Mus musculus 127-130 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 14-22 mechanistic target of rapamycin kinase Mus musculus 131-135 30050135-0 2018 Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. ricolinostat 14-22 mitogen-activated protein kinase 1 Mus musculus 140-143 30050135-1 2018 Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers. ricolinostat 0-12 histone deacetylase 6 Mus musculus 52-57 30050135-1 2018 Ricolinostat (ACY-1215), a first-in-class selective HDAC6 inhibitor, exhibits antitumor effects alone or in combination with other drugs in various cancers. ricolinostat 14-22 histone deacetylase 6 Mus musculus 52-57 30050135-5 2018 We further demonstrated that ACY-1215 treatment reduced the expression of PI3K, P-AKT, P-mTOR, and P-ERK1/2 and increased that of Ac-H3K9 and Ac-H4K8. ricolinostat 29-37 thymoma viral proto-oncogene 1 Mus musculus 82-85 30050135-5 2018 We further demonstrated that ACY-1215 treatment reduced the expression of PI3K, P-AKT, P-mTOR, and P-ERK1/2 and increased that of Ac-H3K9 and Ac-H4K8. ricolinostat 29-37 mechanistic target of rapamycin kinase Mus musculus 89-93 30050135-7 2018 Anti-miR-30d partially rescued the G2/M phase arrest and apoptosis caused by ACY-1215 treatment. ricolinostat 77-85 microRNA 30d Mus musculus 5-12 30050135-10 2018 In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC. ricolinostat 37-45 microRNA 30d Mus musculus 106-113 30050135-10 2018 In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC. ricolinostat 37-45 thymoma viral proto-oncogene 1 Mus musculus 119-122 30050135-10 2018 In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC. ricolinostat 37-45 mechanistic target of rapamycin kinase Mus musculus 123-127 30050135-10 2018 In conclusion, our study showed that ACY-1215 suppressed proliferation and promoted apoptosis in ESCC via miR-30d/PI3K/AKT/mTOR and ERK pathways and that ACY-1215 may be a promising antitumor agent in ESCC. ricolinostat 37-45 mitogen-activated protein kinase 1 Mus musculus 132-135 30043566-3 2018 ACY 1215 (ricolinostat), a selective HDAC6 inhibitor, is currently being clinically trialed in multiple cancers but not in melanoma. ricolinostat 0-8 histone deacetylase 6 Mus musculus 37-42 30043566-3 2018 ACY 1215 (ricolinostat), a selective HDAC6 inhibitor, is currently being clinically trialed in multiple cancers but not in melanoma. ricolinostat 10-22 histone deacetylase 6 Mus musculus 37-42 29112935-0 2018 Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-kappaB pathway. ricolinostat 32-40 histone deacetylase 6 Mus musculus 0-21 29483217-8 2018 Mechanistically, we found that the apoptosis following combined Carfilzomib/ACY-1215 treatment is mediated through increased CHOP expression. ricolinostat 76-84 DNA damage inducible transcript 3 Homo sapiens 125-129 29112935-0 2018 Histone deacetylase 6 inhibitor ACY-1215 protects against experimental acute liver failure by regulating the TLR4-MAPK/NF-kappaB pathway. ricolinostat 32-40 toll-like receptor 4 Mus musculus 109-113 29112935-2 2018 ACY-1215 is a selective histone deacetylase 6 inhibitor, and it has been recognized as a potential anticancer and anti-inflammation drug. ricolinostat 0-8 histone deacetylase 6 Mus musculus 24-45 29112935-14 2018 Pretreatment of ACY-1215 significantly decreased the protein expression of TLR4 and the activation of MAPK and NF-kappaB signalling pathways. ricolinostat 16-24 toll-like receptor 4 Mus musculus 75-79 29112935-15 2018 ACY-1215 has potential therapeutic value in mice with ALF by directly inhibiting inflammatory response via regulation of the TLR4-MAPK/NF-kB pathway. ricolinostat 0-8 toll-like receptor 4 Mus musculus 125-129 28270494-11 2017 Combination of SJB and HDACi ACY-1215, bortezomib, lenalidomide, or pomalidomide triggers synergistic cytotoxicity.Conclusions: Our preclinical studies provide the framework for clinical evaluation of USP1 inhibitors, alone or in combination, as a potential novel multiple myeloma therapy. ricolinostat 29-37 ubiquitin specific peptidase 1 Homo sapiens 201-205 28747357-0 2017 An inhibitor of histone deacetylase 6 activity, ACY-1215, reduces cAMP and cyst growth in polycystic kidney disease. ricolinostat 48-56 histone deacetylase 6 Mus musculus 16-37 28747357-4 2017 Treatment with ACY-1215 slowed cyst growth in a mouse model of ADPKD that forms massive cysts within 3 wk after knockout of polycystin 1 function. ricolinostat 15-23 polycystin 1, transient receptor potential channel interacting Mus musculus 124-136 28747357-7 2017 We found that ACY-1215 lowered cAMP levels and protein expression of adenylyl cyclase 6. ricolinostat 14-22 adenylate cyclase 6 Mus musculus 69-87 27589363-5 2017 Clustering analysis allowed identifying the most populated conformers present during the MD simulation, which were used as starting models to perform docking calculations with five DD2-HDAC6 inhibitors: Cay10603 (CAY), Rocilinostat (RCT), Tubastatin A (TBA), Tubacin (TBC), and Nexturastat (NXT), and then were also submitted to 100-ns-long MD simulations. ricolinostat 233-236 histone deacetylase 6 Homo sapiens 181-190 29108192-5 2017 ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05). ricolinostat 0-7 glutamic pyruvic transaminase, soluble Mus musculus 103-106 29108192-5 2017 ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05). ricolinostat 0-7 solute carrier family 17 (anion/sugar transporter), member 5 Mus musculus 108-111 29108192-5 2017 ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05). ricolinostat 0-7 tumor necrosis factor Mus musculus 128-137 29108192-5 2017 ACY1215 significantly improved the pathological damage in liver tissue and reduced the serum levels of ALT, AST, blood ammonia, TNF-alpha, and IFN-gamma (t<=-3.515, all P < 0.05). ricolinostat 0-7 interferon gamma Mus musculus 143-152 29108192-6 2017 ACY1215 also significantly reduced the expression of NF-kappaB-p65 (t = -5.871, P = 0.004) and the mRNA expression of TNF-alpha (t = -11.913, P < 0.01) in brain tissue and brain water content (t = -2.355, P < 0.01). ricolinostat 0-7 tumor necrosis factor Mus musculus 118-127 28452069-5 2017 This effect was specific for tubacin, as inhibition of HDAC6 deacetylase activity by another selective HDAC6 inhibitor, ACY-1215 or the pan-HDAC inhibitor trichostatin A (TSA), and knockdown of HDAC6 did not enhance the release of CD133+ EVs. ricolinostat 120-128 histone deacetylase 6 Homo sapiens 55-60 28452069-5 2017 This effect was specific for tubacin, as inhibition of HDAC6 deacetylase activity by another selective HDAC6 inhibitor, ACY-1215 or the pan-HDAC inhibitor trichostatin A (TSA), and knockdown of HDAC6 did not enhance the release of CD133+ EVs. ricolinostat 120-128 histone deacetylase 9 Homo sapiens 55-59 28819043-6 2017 We also showed that late administration of ACY-1215 and tubastatin A, two potent and selective inhibitors of HDAC6, rescued the tau-induced MT defects after the abnormalities had already become apparent. ricolinostat 43-51 histone deacetylase 6 Homo sapiens 109-114 28819043-6 2017 We also showed that late administration of ACY-1215 and tubastatin A, two potent and selective inhibitors of HDAC6, rescued the tau-induced MT defects after the abnormalities had already become apparent. ricolinostat 43-51 microtubule associated protein tau Homo sapiens 128-131 28408401-4 2017 By evaluating human peripheral blood and NSCLC tumors, we show that the selective HDAC6 inhibitor ricolinostat promotes phenotypic changes that support enhanced T-cell activation and improved function of antigen-presenting cells. ricolinostat 98-110 histone deacetylase 6 Homo sapiens 82-87 27957719-8 2017 Three different inhibitors (ACY-738, ACY-775, and ACY-1215) were tested and demonstrated to be both potent and selective HDAC6 inhibitors. ricolinostat 50-58 histone deacetylase 6 Mus musculus 121-126 28315173-0 2017 Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine. ricolinostat 0-12 histone deacetylase 6 Homo sapiens 26-31 28267067-7 2017 These findings were confirmed using the established HDAC6 inhibitor ACY-1215 (Ricolinostat), which is currently in clinical trials for cancer treatment. ricolinostat 68-76 histone deacetylase 6 Mus musculus 52-57 28267067-7 2017 These findings were confirmed using the established HDAC6 inhibitor ACY-1215 (Ricolinostat), which is currently in clinical trials for cancer treatment. ricolinostat 78-90 histone deacetylase 6 Mus musculus 52-57 28053023-0 2017 Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. ricolinostat 0-12 histone deacetylase 9 Homo sapiens 34-53 27993968-3 2017 ACY-1215 (ricolinostat) is a first-in-class selective HDAC6 inhibitor. ricolinostat 0-8 histone deacetylase 6 Homo sapiens 54-59 27993968-3 2017 ACY-1215 (ricolinostat) is a first-in-class selective HDAC6 inhibitor. ricolinostat 10-22 histone deacetylase 6 Homo sapiens 54-59 27993968-10 2017 In vivo confirmation of antitumor synergy was demonstrated with a xenograft of DLBCL.Conclusions: The development of this ACY-1215-resistant cell line has provided valuable insights into the mechanistic role of HDAC6 in lymphoma and offered a novel method to identify rational synergistic drug combinations. ricolinostat 122-130 histone deacetylase 6 Homo sapiens 211-216 26116270-0 2015 Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. ricolinostat 82-90 histone deacetylase 6 Mus musculus 66-71 28076695-8 2017 Early data from clinical trials investigating the HDAC6 inhibitor ricolinostat are also discussed. ricolinostat 66-78 histone deacetylase 6 Homo sapiens 50-55 27884726-6 2017 Ricolinostat and ACY-241, which selectively inhibit HDAC6 and the aggresome pathway, are currently being studied in combination with dexamethasone and bortezomib or an immunomodulatory drug for the treatment of relapsed and refractory MM. ricolinostat 0-12 histone deacetylase 6 Homo sapiens 52-57 27646843-2 2016 Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically. ricolinostat 0-12 histone deacetylase 6 Homo sapiens 52-57 27646843-2 2016 Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically. ricolinostat 0-12 histone deacetylase 9 Homo sapiens 52-56 27646843-2 2016 Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically. ricolinostat 14-22 histone deacetylase 6 Homo sapiens 52-57 27646843-2 2016 Ricolinostat (ACY-1215) is the first oral selective HDAC6 inhibitor with reduced class I HDAC activity to be studied clinically. ricolinostat 14-22 histone deacetylase 9 Homo sapiens 52-56 27646843-19 2016 INTERPRETATION: The findings from this study provide preliminary evidence that ricolinostat is a safe and well tolerated selective HDAC6 inhibitor, which might partner well with lenalidomide and dexamethasone to enhance their efficacy in relapsed or refractory multiple myeloma. ricolinostat 79-91 histone deacetylase 6 Homo sapiens 131-136 26643555-9 2015 We thus demonstrated that Ricolinostat (ACY1215), a leading HDAC6 inhibitor, efficiently controls IBC cell proliferation both in vitro and in vivo. ricolinostat 26-38 histone deacetylase 6 Homo sapiens 60-65 26643555-9 2015 We thus demonstrated that Ricolinostat (ACY1215), a leading HDAC6 inhibitor, efficiently controls IBC cell proliferation both in vitro and in vivo. ricolinostat 40-47 histone deacetylase 6 Homo sapiens 60-65 26150340-3 2015 GBM cell growth was significantly inhibited by ACY-1215, a specific HDAC6 inhibitor. ricolinostat 47-55 histone deacetylase 6 Homo sapiens 68-73 28035401-0 2017 ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. ricolinostat 0-8 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens 55-59 28035401-0 2017 ACY-1215 accelerates vemurafenib induced cell death of BRAF-mutant melanoma cells via induction of ER stress and inhibition of ERK activation. ricolinostat 0-8 mitogen-activated protein kinase 1 Homo sapiens 127-130 28035401-7 2017 ACY-1215, a selective HDAC6 inhibitor, inhibits the proliferation and induces the apoptosis of A375 cells. ricolinostat 0-8 histone deacetylase 6 Homo sapiens 22-27 28035401-8 2017 Moreover, ACY-1215 sensitizes A375 cells to vemurafenib induced cell proliferation inhibition and apoptosis induction, which occur partly through induction of endoplasmic reticulum (ER) stress and inactivation of extracellular signal-regulated kinase (ERK). ricolinostat 10-18 mitogen-activated protein kinase 1 Homo sapiens 213-250 28035401-8 2017 Moreover, ACY-1215 sensitizes A375 cells to vemurafenib induced cell proliferation inhibition and apoptosis induction, which occur partly through induction of endoplasmic reticulum (ER) stress and inactivation of extracellular signal-regulated kinase (ERK). ricolinostat 10-18 mitogen-activated protein kinase 1 Homo sapiens 252-255 26116270-4 2015 We investigated the mechanism and therapeutic impact of the selective HDAC6 inhibitor ACY-1215 alone and in combination with bortezomib in preclinical models of lymphoma. ricolinostat 86-94 histone deacetylase 6 Mus musculus 70-75 25239935-0 2014 In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. ricolinostat 62-74 histone deacetylase 6 Homo sapiens 46-51 25978432-7 2015 Importantly ACY1215, an HDAC6 inhibitor with minimal effects on class-I HDACs, together with Len induces synergistic MM cytotoxicity without alteration of CRBN expression. ricolinostat 12-19 histone deacetylase 6 Homo sapiens 24-29 25458911-6 2015 METHODS: We assessed the clinical and biological effects of ACY-1215, an HDAC6-specific inhibitor, by using murine CD8 T cell-related skin disease models, including contact hypersensitivity (CHS) and experimental graft-versus-host disease (GVHD)-like disease. ricolinostat 60-68 histone deacetylase 6 Mus musculus 73-78 25239935-0 2014 In vitro and in vivo interactions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells. ricolinostat 76-83 histone deacetylase 6 Homo sapiens 46-51 25239935-7 2014 Combined exposure to carfilzomib and ricolinostat also markedly downregulated the cargo-loading protein HR23B. ricolinostat 37-49 RAD23 homolog B, nucleotide excision repair protein Homo sapiens 104-109 25239935-8 2014 Moreover, HR23B knockdown significantly increased carfilzomib- and ricolinostat-mediated lethality, suggesting a role for this event in cell death. ricolinostat 67-79 RAD23 homolog B, nucleotide excision repair protein Homo sapiens 10-15 22262760-0 2012 Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. ricolinostat 102-110 histone deacetylase 6 Homo sapiens 85-90 24434010-6 2014 Furthermore, pharmacological inhibition of HDAC6 by Tubastatin-A, Tubacin, and ACY-1215 decreased proliferation of cystic cholangiocytes in a dose- and time-dependent manner, and inhibited cyst growth in three-dimensional cultures. ricolinostat 79-87 histone deacetylase 6 Rattus norvegicus 43-48 24434010-7 2014 Importantly, ACY-1215 administered to PCK rats diminished liver cyst development and fibrosis. ricolinostat 13-21 phosphoenolpyruvate carboxykinase 1 Rattus norvegicus 38-41 24471924-4 2014 In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat. ricolinostat 333-345 chorionic somatomammotropin hormone 1 Homo sapiens 191-194 22262760-3 2012 In the present study, we investigated the preclinical activity of ACY-1215, an HDAC6-selective inhibitor, alone and in combination with bortezomib in MM. ricolinostat 66-74 histone deacetylase 6 Homo sapiens 79-84 22262760-4 2012 Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase. ricolinostat 13-21 caspase 3 Homo sapiens 172-181 22262760-4 2012 Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase. ricolinostat 13-21 caspase 8 Homo sapiens 183-192 22262760-4 2012 Low doses of ACY-1215 combined with bortezomib triggered synergistic anti-MM activity, resulting in protracted endoplasmic reticulum stress and apoptosis via activation of caspase-3, caspase-8, and caspase-9 and poly (ADP) ribosome polymerase. ricolinostat 13-21 caspase 9 Homo sapiens 198-207 22262760-7 2012 Pharmacokinetic data showed peak plasma levels of ACY-1215 at 4 hours after treatment coincident with an increase in acetylated alpha-tubulin, a marker of HDAC6 inhibition, by immunohistochemistry and Western blot analysis. ricolinostat 50-58 histone deacetylase 6 Homo sapiens 155-160